Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

312
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
312
In Vitro Drug Dissolution: Compendial Testing Models II01:09

In Vitro Drug Dissolution: Compendial Testing Models II

340
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
340
Testes: Histology01:27

Testes: Histology

3.1K
A tough, fibrous membrane, the tunica albuginea, covers the testes, extending inward to form fibrous partitions or septa, dividing them into internal compartments called lobules. Each lobule has 1 to 3 tightly coiled seminiferous tubules where sperm production occurs. These tubules merge into a tubular network at the back of the testis, known as the rete testis. It connects to 15 to 20 efferent ductules, leading to the epididymis.
The spermatogenic cells, responsible for producing sperm, are...
3.1K
Complementation Tests00:49

Complementation Tests

6.3K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
6.3K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.6K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.6K
Significance Testing: Overview01:04

Significance Testing: Overview

12.8K
Significance testing is a set of statistical methods used to test whether a claim about a parameter is valid. In analytical chemistry, significance testing is used primarily to determine whether the difference between two values comes from determinate or random errors. The effect of a particular change in the measurement protocol, analyst, or sample itself can cause a deviation from the expected result. In the case of a suspected deviation/outlier, we need to be able to confirm mathematically...
12.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidance on communication and informed consent with patients and their families for experimental individualized treatments.

American journal of human genetics·2026
Same author

Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies.

Orphanet journal of rare diseases·2026
Same author

Unraveling the spatial landscape of dystrophinopathies: a transcriptomic approach to Becker and Duchenne muscular dystrophies.

The Journal of pathology·2026
Same author

TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT.

Journal of neuromuscular diseases·2026
Same author

Myonuclear Domain-Associated and Central Nucleation-Dependent Spatial Restriction of Dystrophin Protein Expression.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study.

Nucleic acid therapeutics·2026

Related Experiment Video

Updated: Feb 14, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.

Marcel Veltrop1, Laura van Vliet1, Margriet Hulsker1

  • 1Department of Human Genetics, Leiden University Medical Center, Leiden, RC, the Netherlands.

Plos One
|February 22, 2018
PubMed
Summary

A novel mouse model, del52hDMD/mdx, allows testing of human-specific antisense oligonucleotide therapies for Duchenne muscular dystrophy (DMD). This model enables in vivo analysis of exon skipping and dystrophin restoration for improved DMD treatments.

More Related Videos

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.7K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.4K

Related Experiment Videos

Last Updated: Feb 14, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.7K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.4K

Area of Science:

  • Genetics
  • Molecular Biology
  • Neurology

Background:

  • Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by mutations in the DMD gene, leading to a lack of functional dystrophin protein.
  • Antisense oligonucleotide (AON)-mediated exon skipping offers a therapeutic strategy to restore the reading frame and produce partially functional dystrophin, as seen in Becker muscular dystrophy.
  • Existing mouse models have limitations for testing human-specific AONs due to interspecies genetic variations.

Purpose of the Study:

  • To develop and validate a novel mouse model for evaluating human-specific AON therapies for Duchenne muscular dystrophy.
  • To enable in vivo assessment of AON efficacy on RNA and protein levels, as well as muscle function.
  • To facilitate optimization of AONs and genome editing approaches for DMD treatment.

Main Methods:

  • Generation of the del52hDMD/mdx mouse model, which carries both murine and human DMD genes with specific mutations.
  • Abolition of mouse dystrophin expression via a stop mutation in exon 23 and human dystrophin expression via exon 52 deletion.
  • Local administration of human-specific morpholino antisense oligonucleotides to induce exon skipping and dystrophin restoration.

Main Results:

  • The del52hDMD/mdx mouse model exhibits histological and mild functional impairments characteristic of muscular dystrophy.
  • Human-specific morpholinos successfully induced exon skipping and restored dystrophin expression in the del52hDMD/mdx mice.
  • Low-level skipping of the murine Dmd gene was occasionally observed, depending on AON mismatch numbers.

Conclusions:

  • The del52hDMD/mdx mouse model is a valuable tool for the in vivo analysis of human-specific AONs targeting DMD.
  • This model allows for the assessment of AONs targeting specific exons (e.g., exon 51 or 53) on RNA, protein, muscle quality, and function.
  • The del52hDMD/mdx model will aid in optimizing AON therapies and genome editing strategies for Duchenne muscular dystrophy.